Centessa Pharmaceuticals reported positive initial Phase 2a results for ORX750, its oral OX2R agonist, across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, and set plans to initiate a registrational program in the first quarter of 2026. The update also advanced two additional OX2R agonists: ORX142, which showed favorable Phase 1 pharmacology with rapid onset and plans to enter patient studies in early 2026, and ORX489, expected to begin clinical testing pending IND clearance in the same timeframe. With $349 million in cash, equivalents, and investments as of September 30, 2025, and a runway projected into mid-2027, the company signaled its capacity to prosecute multi-indication development.
The strategic question is whether Centessa can convert early, cross-indication efficacy into class leadership and commercial displacement of entrenched symptomatic therapies. In the 55-participant initial cohorts of the CRYSTAL-1 study, ORX750 demonstrated statistically significant, clinically meaningful, and dose-dependent improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale across all three conditions, alongside an 87% relative reduction in weekly cataplexy rate in narcolepsy type 1 at a 1.5 mg dose over two weeks. Narcolepsy type 2 participants at 4 mg achieved a mean sleep latency increase of more than 10 minutes compared with placebo, and idiopathic hypersomnia participants at 2 mg showed significant improvements across multiple measures. Safety was generally favorable with mostly mild to moderate adverse events; notably, there were no clinically meaningful cardiac, visual, hepatic, or renal signals in these early cohorts, a critical consideration for a class that previously encountered liver toxicity with an early competitor. Pollakiuria, insomnia, dizziness, and headache were the most common events, and dose optimization is ongoing with once-daily and split-dose regimens.
Why this matters now: orexin agonism is poised to recast the care of hypersomnolence from broad wake-promotion to targeted neurotransmitter restoration. If sustained in larger, longer trials, cross-indication efficacy positions ORX750 to reshape a market currently dominated by oxybates, histaminergic agents, and dopamine/norepinephrine reuptake inhibitors. For patients, the prospect is normalization of wakefulness and control of cataplexy with a once-daily oral therapy. For payers, the decision calculus will hinge on functional outcomes, durability, safety at scale, and utility in underdiagnosed populations like idiopathic hypersomnia, where prevalence and work productivity implications could drive meaningful budget impact. Head-to-head trials are unlikely, placing a premium on robust indirect comparisons, consistent responder definitions, and real-world evidence on accidents, absenteeism, and quality of life.
Medical Affairs teams should prepare for intensive education in sleep centers and beyond, clarifying orexin biology, differentiating efficacy from stimulants and oxybates, and guiding patient selection. Managing urinary frequency and insomnia in routine practice, along with the transition from short crossover cohorts to longer-term use, will be pivotal to uptake and adherence. Diagnostic enablement remains a gating factor; partnerships to streamline pathways to MSLT/MWT access and to standardize scales could accelerate identification and treatment.
Commercially, a first-in-class label in narcolepsy type 2 or idiopathic hypersomnia could be the most disruptive wedge, given fewer mechanism-driven options and growing payer openness to therapies that deliver measurable daytime function. The broader pipeline hints at expansion beyond hypersomnolence into fatigue and attention domains, but that will require a distinct evidence base and careful risk-benefit framing.
The following proof points are clear: dose-escalation data from the parallel cohorts, the design and endpoints of the registrational program, and signals of durability and safety over months rather than weeks. The competitive race is underway; the winner will be the program that turns compelling short-term physiology into long-term functional value acceptable to regulators, clinicians, and payers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
